Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ATROPINE CRS (30 MG)

ATROPINE CRS (30 MG)

51-55-8

DISCOVER
DESFLURANE - REFERENCE SPECTRUM (N/A)

DESFLURANE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
INDINAVIR SULFATE - REFERENCESPECTRUM (N/A)

INDINAVIR SULFATE - REFERENCESPECTRUM (N/A)

NA

DISCOVER
IBUPROFEN FOR PEAK IDENTIFICATION CRS (0.09 MG)

IBUPROFEN FOR PEAK IDENTIFICATION CRS (0.09 MG)

15687-27-1

DISCOVER
ADRENALINE CRS (15 MG)

ADRENALINE CRS (15 MG)

51-43-4

DISCOVER
Adrenaline with impurity F CRS, 0.008mg

Adrenaline with impurity F CRS, 0.008mg

51-43-4

DISCOVER
CARPROFEN FOR SYSTEM SUITABILITY CRS (5 MG)

CARPROFEN FOR SYSTEM SUITABILITY CRS (5 MG)

53716-49-7

DISCOVER
CLODRONATE IMPURITY D CRS (5 MG)

CLODRONATE IMPURITY D CRS (5 MG)

NA

DISCOVER
CYCLIZINE IMPURITY A CRS (15 MG)

CYCLIZINE IMPURITY A CRS (15 MG)

109-01-3

DISCOVER
CYCLIZINE IMPURITY B CRS (15 MG)

CYCLIZINE IMPURITY B CRS (15 MG)

91-01-0

DISCOVER
CLODRONATE DISODIUM TETRAHYDRATE CRS (5 MG)

CLODRONATE DISODIUM TETRAHYDRATE CRS (5 MG)

22560-50-5

DISCOVER
FLUCLOXACILLIN IMPURITY C CRS(5 MG)

FLUCLOXACILLIN IMPURITY C CRS(5 MG)

551-16-6

DISCOVER